3-MeO-PCMo (3-methoxyphencyclomorpholine) is a synthetic dissociative of the arylcyclohexylamine class, a morpholine-ring analog of 3-MeO-PCP and structural cousin to PCMo. The methoxymorpholine substitution distinguishes it from both straight-chain aminoalkyl analogs (like PCP) and ketamine-type structures. Community experience with 3-MeO-PCMo is relatively limited compared to the broader catalog of novel dissociatives, placing it among the less well-characterized compounds in this class.
Based on structural similarity to 3-MeO-PCP, 3-MeO-PCMo is expected to act as an NMDA receptor antagonist with likely sigma receptor and dopaminergic activity. The pharmacological character is anticipated to resemble 3-MeO-PCP in its stimulant-dissociative profile while potentially differing in potency and duration due to the morpholine ring's metabolic and pharmacokinetic effects.
The limited community experience data and absence of formal pharmacological research place 3-MeO-PCMo in the high-uncertainty category. Users should approach it with the caution appropriate to any poorly characterized novel psychoactive substance: start with very low doses, use in a controlled environment with a sober companion, and recognize that harm reduction guidance is necessarily extrapolated from better-understood analogs.
Safety at a Glance
High Risk- Apply 3-MeO-PCP Harm Reduction Principles
- In the absence of specific safety data, apply the harm reduction framework developed for 3-MeO-PCP to 3-MeO-PCMo:
- Toxicity: Uncertainty as a Primary Risk Factor The most important toxicity consideration for 3-MeO-PCMo is the absence of syste...
- Dangerous with: Acetylfentanyl, Buprenorphine, Codeine, Desomorphine (+15 more)
- Overdose risk: Overdose on 3-MeO-PCMo can range from unpleasant to life-threatening depending on the dose, route...
If someone is in crisis, call 911 or Poison Control: 1-800-222-1222
Dosage
oral
Duration
oral
Total: 5 hrs – 6 hrsHow It Feels
The onset is gentle and almost tentative, as though the compound is politely introducing itself before committing to anything. A mild heaviness settles over the body within fifteen or twenty minutes — nothing dramatic, just a softening of physical tension, a subtle unclenching of muscles you did not realize were tight. The world takes on a faintly muted quality, as though someone has placed a single sheet of tissue paper between you and your surroundings. It is a whisper of dissociation, not a shout.
As the effects develop over the next half hour, the experience remains firmly in the shallow end of the dissociative pool. Sound acquires a very slight echo, as if the room has grown marginally larger. Vision is mostly unaffected, though there may be a faint softness to light sources, a barely perceptible glow around lamps and screens. The body feels comfortable and slightly heavy — not leaden, but pleasantly anchored, as though gravity has been gently increased by a fraction. Thoughts slow a notch, shedding some of their usual urgency, and there is a quiet contentment to simply sitting and observing.
The peak, such as it is, arrives within an hour and presents itself as a mild plateau of calm detachment. You can think clearly, move normally, and hold conversation without difficulty. What has changed is the emotional weather: anxiety has receded, replaced by a neutral, observational state that is neither euphoric nor flat. It is the experience of watching rain from behind a window — you can see it, understand it, but you are not getting wet. Closed-eye visuals are minimal or absent. Music sounds slightly richer, slightly more textured, but the enhancement is subtle.
The entire experience is brief — two to three hours at most — and the descent is so gradual as to be almost imperceptible. You simply notice, at some point, that the tissue paper has been removed and the world is back to its usual density. There is no crash, no rebound anxiety, no lingering stimulation. Sleep comes easily if the timing is right. The compound leaves behind almost nothing — no afterglow, no residual warmth, just a quiet return to baseline, as though you had taken a very brief and very mild vacation from the weight of being yourself.
Subjective Effects
The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.
Physical Effects
Physical(8)
- Motor control loss— A distinct decrease in the ability to control one's physical body with precision, balance, and coord...
- Nausea— An uncomfortable sensation of queasiness and stomach discomfort that may or may not lead to vomiting...
- Pain relief— A suppression of negative physical sensations such as aches and pains, ranging from dulled awareness...
- Perception of bodily lightness— Perception of bodily lightness is the subjective feeling that one's body has become dramatically lig...
- Physical autonomy— Physical autonomy is the experience of one's body performing actions — from simple tasks like walkin...
- Physical euphoria— An intensely pleasurable bodily sensation that can manifest as waves of warmth, tingling electricity...
- Spatial disorientation— Spatial disorientation is the inability to accurately perceive one's position or orientation within ...
- Stimulation— A state of heightened physical and mental energy characterized by increased wakefulness, elevated mo...
Tactile(1)
- Tactile suppression— A progressive decrease in the ability to feel physical touch, ranging from mild numbness to complete...
Cognitive & Perceptual Effects
Visual(6)
- Double vision— The visual experience of seeing a single object as two separate, overlapping images, similar to cros...
- Frame rate suppression— Perception of visual motion as choppy discrete frames rather than smooth continuous flow, resembling...
- Geometry— The experience of perceiving complex, ever-shifting geometric patterns superimposed over the visual ...
- Perspective distortions— Distortion of perceived depth, distance, and size of real objects, making things appear closer, furt...
- Visual acuity suppression— Vision becomes blurred, indistinct, and out of focus, as though looking through a smudged lens. Fine...
- Visual disconnection— A dissociative visual effect involving a progressive detachment from visual perception, ranging from...
Cognitive(19)
- Amnesia— A complete or partial inability to form new memories or recall existing ones during and after substa...
- Analysis suppression— Analysis suppression is a cognitive impairment in which the capacity for logical reasoning, critical...
- Anxiety— Intense feelings of apprehension, worry, and dread that can range from a subtle background unease to...
- Anxiety suppression— A partial to complete suppression of anxiety and general unease, producing a calm, relaxed mental st...
- Compulsive redosing— An overwhelming, difficult-to-resist urge to continuously take more of a substance in order to maint...
- Conceptual thinking— A shift in the nature of thought from verbal, linear sentence structures to intuitive, non-linguisti...
- Creativity enhancement— An increase in the ability to imagine new ideas, overcome creative blocks, think about existing conc...
- Deja vu— Intense, often prolonged sensation of having already experienced the current moment, common with psy...
- Depersonalization— A detachment from one's own sense of self, body, or mental processes, as if observing oneself from o...
- Derealization— A perceptual disturbance in which the external world feels profoundly unreal, dreamlike, or artifici...
- Disinhibition— A marked reduction in social inhibitions, self-consciousness, and behavioral restraint that manifest...
- Dream potentiation— Enhanced dream vividness, complexity, and recall, often occurring as REM rebound after discontinuing...
- Immersion enhancement— A heightened capacity to become fully absorbed and engrossed in external media such as music, films,...
- Introspection— An enhanced state of self-reflective awareness in which one feels drawn to examine their own thought...
- Mania— Abnormally elevated mood, energy, and activity with impulsive behavior and grandiosity, associated w...
- Memory suppression— A dose-dependent inhibition of one's ability to access and utilize short-term and long-term memory, ...
- Psychosis— Psychosis is a serious psychiatric state involving a fundamental break from consensus reality — char...
- Thought deceleration— The experience of thoughts occurring at a markedly reduced pace, as if the mind has been placed into...
- Time distortion— Subjective perception of time becomes dramatically altered — minutes may feel like hours, or hours p...
Transpersonal(2)
- Ego death— A profound dissolution of the sense of self in which personal identity, memories, and the boundary b...
- Existential self-realization— A sudden, visceral realization of the profound significance and improbability of one's own existence...
Pharmacology
Inferred Mechanism
3-MeO-PCMo's pharmacology is not characterized by formal research. Based on its arylcyclohexylamine structure and structural relationship to 3-MeO-PCP and PCMo, it is inferred to act primarily as an NMDA receptor antagonist through the non-competitive, open-channel blocking mechanism shared by all compounds in this class.
The 3-methoxy substitution on the phenyl ring — shared with 3-MeO-PCP — suggests similar sigma receptor activity and dopaminergic engagement to its close analog, with the associated stimulant and mood-elevating properties.
Morpholine Ring Effects
The morpholine ring (a six-membered ring containing both oxygen and nitrogen) replaces the piperidine or other nitrogen-containing rings found in PCP and other analogs. The oxygen atom in the morpholine ring alters the electronic properties and metabolic handling of the compound, potentially affecting:
- Pharmacokinetic profile (absorption, distribution, metabolism, elimination)
- Duration of effects
- Metabolite profile
Whether these changes produce clinically meaningful differences from 3-MeO-PCP in the human experience is not established from formal data.
Expected Effect Profile
By analogy with 3-MeO-PCP, 3-MeO-PCMo is expected to produce:
Detection Methods
Standard Drug Panel Inclusion
3-MeO-PCMo is NOT expected to trigger a positive result on standard PCP immunoassay screens. The morpholine ring substitution significantly alters the molecular geometry compared to PCP, reducing immunoassay cross-reactivity. Standard drug panels will return negative results for this compound.
Urine Detection
Limited pharmacokinetic data exists for 3-MeO-PCMo. Based on structural considerations, urine detection windows are estimated at 2 to 5 days after a single dose. The morpholine ring may undergo oxidative metabolism, and the methoxy group is likely subject to O-demethylation. Reliable detection requires LC-MS/MS methods specifically targeting 3-MeO-PCMo and its predicted metabolites.
Blood and Serum Detection
Blood detection parameters have not been systematically studied. Detection windows are estimated at 1 to 2 days based on the compound's structural characteristics. Forensic case reports, if available, would provide the primary source of concentration data.
Hair Follicle Detection
No validated hair testing methods exist for 3-MeO-PCMo. The compound's novel structure limits the availability of forensic analytical data.
Confirmatory Methods
LC-MS/MS is the only practical approach for confirmation. Reference standards may need to be custom synthesized or obtained from specialized suppliers. The morpholine ring produces characteristic mass spectral fragmentation patterns that can aid identification.
Reagent Testing
No established reagent testing protocols exist for 3-MeO-PCMo. Reactions with standard reagents are expected to be similar to other methoxylated dissociatives but have not been systematically documented. Fentanyl test strips should be used on any product obtained from unregulated markets.
Interactions
| Substance | Status | Note |
|---|---|---|
| Acetylfentanyl | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Buprenorphine | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Codeine | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Desomorphine | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Dextropropoxyphene | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Dihydrocodeine | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Ethylmorphine | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Fentanyl | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Heroin | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Hydrocodone | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Hydromorphone | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Kratom | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Methadone | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Morphine | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Naloxone | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| O-Desmethyltramadol | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Oxycodone | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Oxymorphone | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Pethidine | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| 1,4-Butanediol | Caution | Both cause CNS depression; increased risk of vomiting, unconsciousness, and respiratory depression |
| 2-Fluorodeschloroketamine | Caution | Compounding dissociative effects can cause confusion, mania, and loss of motor control |
| 2M2B | Caution | Both cause CNS depression; increased risk of vomiting, unconsciousness, and respiratory depression |
| 3-Cl-PCP | Caution | Compounding dissociative effects can cause confusion, mania, and loss of motor control |
| 3-HO-PCE | Caution | Compounding dissociative effects can cause confusion, mania, and loss of motor control |
| 1,3-Butanediol | Low Risk & Synergy | Produces unique synergistic effects; often combined |
| 1B-LSD | Low Risk & Synergy | Produces unique synergistic effects; often combined |
| 1cP-AL-LAD | Low Risk & Synergy | Produces unique synergistic effects; often combined |
| 1cP-LSD | Low Risk & Synergy | Produces unique synergistic effects; often combined |
| 1cP-MiPLA | Low Risk & Synergy | Produces unique synergistic effects; often combined |
History
Development Context
3-MeO-PCMo belongs to the family of arylcyclohexylamine analogs developed through systematic structural modification of PCP and its analogs. The morpholine ring substitution represents one branch of the SAR exploration that produced numerous compounds differing in their ring nitrogen substituents — piperidine (PCP, 3-MeO-PCP), pyrrolidine (PCPr), morpholine (PCMo, 3-MeO-PCMo), and others.
Research Chemical Status
3-MeO-PCMo occupies a niche position in the research chemical landscape — present and available but without the community traction of more popular compounds. Its similarity to 3-MeO-PCP means it offers little that is not already available from its better-studied analog, which has limited its adoption. The small number of community reports reflects this marginal status.
Legal Status
As a structural analog of 3-MeO-PCP and PCP, 3-MeO-PCMo is covered by analogue legislation in many jurisdictions. The specific legal status varies by country and continues to evolve with broader novel psychoactive substance regulation.
Harm Reduction
Apply 3-MeO-PCP Harm Reduction Principles
In the absence of specific safety data, apply the harm reduction framework developed for 3-MeO-PCP to 3-MeO-PCMo:
- Start with very small test doses (2–5 mg range)
- Wait the full expected duration before considering redosing
- Have a sober companion present
- Avoid stimulant combinations
- Treat mania risk as a real concern
Uncertainty Demands Extra Caution
Because 3-MeO-PCMo lacks the community experience base that has informed 3-MeO-PCP harm reduction, treat it with additional caution beyond the already significant caution warranted for 3-MeO-PCP. Unknown potency relative to analogs is a significant risk factor.
Do Not Use as a Substitute for Better-Characterized Analogs
The limited harm reduction data for 3-MeO-PCMo is itself a harm reduction argument for using better-characterized alternatives when the goal is a specific type of experience. The marginal novelty of an obscure analog is not a harm reduction justification for increased risk exposure.
Standard Dissociative Precautions
- Secure physical environment, unable to fall or injure yourself
- No driving or machinery operation
- Bladder protection (limited frequency of use)
- No CNS depressant combinations
Toxicity & Safety
Uncertainty as a Primary Risk Factor
The most important toxicity consideration for 3-MeO-PCMo is the absence of systematic safety data. No formal human toxicology studies exist. Adverse effects documented in community reports (which are sparse) cannot be systematically evaluated for frequency or severity.
Expected Risks by Analogy
Based on structural similarity to 3-MeO-PCP:
- Mania and psychosis risk — the methoxy substitution that confers these risks in 3-MeO-PCP is present in 3-MeO-PCMo; mania risk should be assumed
- Cardiovascular stimulation — elevated heart rate and blood pressure
- Behavioral disinhibition — similar insidious impairment of judgment while feeling capable
- Psychological dependence — euphoric and stimulant character creates potential for compulsive use
Urological Toxicity
As with all arylcyclohexylamines, regular use carries risk of bladder damage analogous to ketamine-associated cystitis.
Unknown Risks
The morpholine ring and its metabolism introduce uncertainties about unique metabolites or unexpected toxicities not present in the better-characterized 3-MeO-PCP. This pharmacological uncertainty should be weighted appropriately in risk assessment.
Addiction Potential
moderately addictive with a high potential for abuse
Overdose Information
Overdose on 3-MeO-PCMo can range from unpleasant to life-threatening depending on the dose, route, and whether other substances are involved.
Signs of overdose: Severe nystagmus, complete unresponsiveness, vomiting (aspiration risk while unconscious), severely depressed breathing, seizures, extremely elevated heart rate or blood pressure.
Critical dangers:
- Respiratory depression: Particularly when combined with other depressants
- Aspiration: Loss of protective reflexes combined with nausea creates choking risk
- Hyperthermia or hypothermia: Impaired thermoregulation at high doses
Emergency response: Place the person in the recovery position. Monitor breathing. Call emergency services if breathing is slow, shallow, or irregular; if the person is unresponsive to stimulation; or if seizures occur. Be honest with medical personnel about what was consumed — they are there to help, not to judge.
Dangerous Interactions
The combinations listed below may be life-threatening. Independent research should always be conducted to ensure safety when combining substances.
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Tolerance
| Full | develops with prolonged and repeated use |
| Half | 3 - 7 days |
| Zero | 1 - 2 weeks |
Cross-tolerances
Legal Status
3-MeO-PCMo is currently thought to be a legal grey area drug worldwide and is easily accessible through the use of online research chemical vendors. However, this does not guarantee anyone to be immune from legal prosecution should they be found in possession of this substance as the legality is likely to vary from country to country.
Germany:** 3-MeO-PCMo is controlled under the NpSG (New Psychoactive Substances Act) as of July 18, 2019. Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.
Switzerland:** 3-MeO-PCMo is a controlled substance specifically named under Verzeichnis E.
United Kingdom** - It is illegal to produce, supply, or import this drug under the Psychoactive Substance Act, which came into effect on May 26th, 2016. While most arylcyclohexylamines are covered by a generic clause, the 1-morpholine group of 3-MeO-PCMo is outside of the definition. While the drug is still controlled under the Psychoactive Substances Act, simple possession (other than within a custodial institution) is not criminalised.
Responsible use
Dissociative
3-MeO-PCMo (Wikipedia)
3-MeO-PCMo (Isomer Design)
3-MeO-PCMo (UK Chemical Research)
3-MeO-PCMo (Bluelight)
Experience Reports (1)
Tips (3)
Tolerance to 3-MeO-PCMo builds with regular use. Taking breaks of at least 1-2 weeks between sessions helps prevent tolerance escalation and reduces the risk of bladder and cognitive damage from frequent use.
Combining 3-MeO-PCMo with stimulants places extreme strain on the cardiovascular system. The opposing effects on heart rate and blood pressure can cause dangerous fluctuations and cardiac events.
Dissociative aftereffects from 3-MeO-PCMo can include cognitive fog, poor coordination, and impaired judgment for hours after the main experience. Do not drive, make important decisions, or use machinery until fully baseline.
See Also
References (3)
- Ketamine as a rapid antidepressant — Berman et al. Biological Psychiatry (2000)paper
- 3-MeO-PCMo - TripSit Factsheet
TripSit factsheet for 3-MeO-PCMo
tripsit - 3-MeO-PCMo - Wikipedia
Wikipedia article on 3-MeO-PCMo
wikipedia